Inicio | Phase II-III study to evaluate the safety and immunogenicity of the pneumococcal vaccine candidate VCN11 in adult participants aged 50 to 74 years.
Publicado clinical_trials Phase II-III study to evaluate the safety and immunogenicity of the pneumococcal vaccine candidate VCN11 in adult participants aged 50 to 74 years. has only one revision
RevisiónEstado
Guardado 27/12/2024 - 10:43am por GladysRevisión actual (publicada)
Equipo de Trabajo del RPCEC | CENCEC - MINSAP
rpcec@cencec.sld.cu
Calle 5ta A Edificio CECMED-CENCEC 2do piso e/ 60 y 62 Miramar, Playa.CP 11300. La Habana, Cuba
Telef: (537) 216-4126 | (537) 216-4212 | (537) 216-4218.
Copyright © 2014-2022 All Rights Reserved.